Veritable’s Theravance Biopharma TBPH Stock Holding History

Veritable’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-6,889	Closed	-$236K	–	829
2017 Q3	$236K	Sell	6,889 -11	-0.2%	-$360	0.01%	684
2017 Q2	$275K	Buy	+6,900	New	+$265K	0.01%	649

Other funds holding TBPH

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Veritable's TBPH Position: Q4 2017 in Review

Veritable sold out of Theravance Biopharma (TBPH) in Q4 2017, closing a stake of 6,889 shares — an estimated $236K sold.

Veritable first reported a position in TBPH in Q2 2017 and held it in 2 quarters. The position peaked at $275K in Q2 2017. 84 funds tracked by Wall St. Rank hold TBPH as of Q4 2017.

Veritable reported no remaining Theravance Biopharma position as of Q4 2017 after selling out during the quarter.
Veritable sold 6,889 Theravance Biopharma shares in Q4 2017, an estimated $236K.
Veritable first reported a position in Theravance Biopharma in Q2 2017 and held it in 2 quarters.
Veritable's Theravance Biopharma position peaked at $275K in Q2 2017.
84 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2017.

Based on Veritable's 13F filing for Q4 2017, filed 13 Feb 2018.